An endoplasmic reticulum transmembrane prolyl 4-hydroxylase (P4H-TM) is able to hydroxylate the α subunit of the hypoxia-inducible factor (HIF) in vitro and in cultured cells, but nothing is known about its roles in mammalian erythropoiesis. We studied such roles here by administering a 
Introduction
Erythropoiesis is a tightly controlled process, its key regulator being erythropoietin (EPO). During embryonic development most of the EPO production occurs in the liver, whereas the major EPO source in adults is the kidney, although the liver maintains a capacity for its expression.
1,2 Hypoxiainducible transcription factor (HIF) plays a pivotal role in the regulation of the transcription of the EPO gene and numerous other hypoxia-regulated genes, including many additional genes influencing erythropoiesis. [1] [2] [3] [4] The HIF-α subunit isoforms HIF-1α and HIF-2α are synthesized constitutively, and hydroxylation of two critical prolines generates 4-hydroxyproline residues that target HIF-α for rapid degradation in normoxia. [5] [6] [7] In hypoxia, this hydroxylation is inhibited, so that HIF-α escapes degradation, translocates into the nucleus, and dimerizes with HIF-β. [5] [6] [7] HIF-1α is expressed in all nucleated cells, whereas HIF-2α expression is restricted to specific cell types, including renal interstitial cells and hepatocytes. 1, 2 Renal and hepatic EPO production in adults is primarily regulated by HIF-2α, but HIF-1α also plays a role in several situations. 1, 2 Erythropoiesis requires iron. Hepcidin, a 25-amino-acid peptide secreted predominantly from hepatocytes, is the central regulator of iron metabolism. It downregulates ferroportin and thus inhibits the absorption of dietary iron and the release of iron form erythrocytes and macrophages. 8, 9 Hepcidin expression is lowered by hypoxia and agents that stabilize HIF-2α leading to increased serum EPO concentration and erythropoiesis, its regulation also involving the hemojuvelin/BMP axis, hemojuvelin cleaving proteins and growth factors. [8] [9] [10] Hepcidin synthesis is increased in inflammatory states and hepcidin appears to play a key role in the pathogenesis of the anemia of chronic disease. 8 Hydroxylation of HIF-α is known to be catalyzed in vertebrates by three HIF prolyl 4-hydroxylase isoenzymes (HIF-P4Hs 1-3, also known as PHDs 1-3 and EglNs 2, 1 and 3). [11] [12] [13] A fourth P4H possessing an endoplasmic reticulum transmembrane domain (P4H-TM) is also able to hydroxylate HIF-α in vitro and in cultured cells, but its roles in the regulation of HIF-α in mammalian tissues in vivo remain to be established. 14, 15 P4H-TM is expressed in many tissues, including the kidney, 15 where the expression is seen in tubular regions of the inner cortex (M. R., P.
Tiainen, J. Hyvärinen, R. Sormunen, I. Miinalainen, R. Soininen, K. I. K., J. M., and P. K., unpublished data, July 2012). All these enzymes are 2-oxoglutarate dioxygenases, which require Fe 2+ , 2-oxoglutarate, O 2 and ascorbate. 16 Hif-p4h-2 null mice die during embryonic development, whereas Hif-p4h-1 and Hif-p4h-3 null mice are viable. 17 Broad-spectrum conditional inactivation of Hif-p4h-2 causes increased Epo production in the kidney, but not in the liver, and severe erythrocytosis, [18] [19] [20] 
whereas hepatic
For personal use only. on June 9, 2017 . by guest www.bloodjournal.org From 4 inactivation of Hif-p4h-2 does not increase serum Epo or blood hematocrit values. 21 We have generated Hif-p4h-2 hypomorphic mice (Hif-p4h-2 gt/gt ) that express lower amounts of wild-type Hifp4h-2 mRNA in various tissues, about 35% of that in wild-type mice in the kidney and 85% in the liver. 22 21 We have also produced P4h-tm -/-mice. These have a mild kidney defect that leads to slight late-onset proteinuria and eye abnormalities that are only seen from about one year onwards (M. R., P. Tiainen, J. Hyvärinen, R.
Sormunen, I. Miinalainen, R. Soininen, K. I. K., J. M., and P. K., unpublished data, July 2012).
Nothing is known about the possible role of P4H-TM in the regulation of erythropoiesis in any mammalian species, but a 3-4-fold increase in the epo mRNA level without any signs of polycythemia was found in p4h-tm-deficient zebrafish embryos.
23
Many small-molecule compounds have been developed that inhibit HIF-P4Hs competitively with respect to 2-oxoglutarate leading to stabilization of HIF-α in cultured cells and in vivo. 16, 24, 25 One such compound, FG-4497, has been shown to stabilize HIF-1α and HIF-2α, to increase the expression of Epo mRNA and several other hypoxia-regulated mRNAs in cultured cells and in vivo and to elevate serum Epo and blood hematocrit values in mice and rats without apparent toxicity, 
Materials and methods

Expression, purification and activity assays of recombinant P4H-TM and HIF-P4Hs
See supplemental Methods for description of enzyme expression, purification and activity assays.
Mouse lines
Only female mice were used here. P4h-tm -/-mice were generated by targeting a LacZNeo cassette into P4h-tm exon 3, leading to a truncated transcript of exons 1-2 and a split exon 3 fused to LacZNeo (M. R., P. Tiainen, J. Hyvärinen, R. Sormunen, I. Miinalainen, R. Soininen, K. I. K., J.
M., and P. K., unpublished data, July 2012). Generation of Hif-p4h-2 gt/gt mice has been described previouly. 22 Hif-p4h-3 -/-mice were generated by replacing Hif-p4h-3 exon 2 with a neo-selection cassette flanked by loxP sites. Correct exon 2 deletion was verified at the cDNA level. 
Blood and serum analyses
See supplemental Methods for blood and serum analyses.
Quantitative real-time RT-PCR (Q-PCR)
See supplemental Methods for Q-PCR.
Western blotting
See supplemental Methods for description of Western blotting.
Statistical analysis
See supplemental Methods for statistical analysis.
Results
Effect of FG-4497 dose
In the initial experiments we determined the FG-4497 concentration required to inhibit purified recombinant human HIF-P4Hs by 50% (IC 50 To study the effect of the FG-4497 dose in vivo, increasing amounts of the compound were given orally to wild-type mice on days 1, 3, 5 and 8, and the mice were sacrificed 6 h after the last dose. A slight degree of Hif-1α stabilization was seen in the kidneys of the mice receiving repeated
For personal use only. on June 9, 2017. by guest www.bloodjournal.org From 7 doses of 6 mg/kg, and the stabilization increased at higher doses ( Figure 1A ). Stabilization of Hif-1α in the liver required a higher dose, being seen only with 60 mg/kg ( Figure 1A ). Serum Epo concentration increased about 3-fold with 20 mg/kg and 6-fold with 60 mg/kg ( Figure 1B) . In an additional similar experiment an oral dose of 100 mg/kg stabilized Hif-1α in the liver even more markedly than 60 mg/kg and Hif-2α was also well stabilized in the kidney and liver ( Figure 1A ).
With a dose of 100 mg/kg serum Epo concentration increased to about 40 times that in the vehicletreated animals ( Figure 1C ). All the experiments reported below were performed using an oral dose of 100 mg/kg.
Effects of FG-4497 on serum Epo concentration
The effects of FG-4497 on serum Epo concentration were studied by administering the compound either only once and sacrificing the mice 6 h later or three times a week (days 1, 3 and 5) for 3-5 weeks and sacrificing the animals 6 h after the last dose. In the 3-week and 5-week experiments the mean serum Epo concentration in the FG-4497-treated P4h-tm -/-mice was about 2.5-fold relative to that in the treated wild-type mice ( Figure 3A ).
In similar experiments with Hif-p4h-2 gt/gt and Hif-p4h-3 -/-mice the serum Epo concentration was about 4-fold in the FG-4497-treated Hif-p4h-2 gt/gt mice relative to treated wild-type mice at 3 weeks ( Figure 3B ), no 5-week experiment being performed with these mice, whereas in the Hif-p4h-3
-/-mice a significant increase in the serum Epo concentration to about 5-fold relative to wild type was seen only at 5 weeks ( Figure 3C ).
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Effects of FG-4497 on stabilization of Hif-1α and Hif-2α and levels of Epo mRNA in the kidney and liver
No stabilization of Hif-1α or Hif-2α was found in the kidney or liver of the vehicle-treated P4h-tm -/-mice, and no difference was seen in the Epo mRNA level in these tissues between the vehicletreated P4h-tm -/-and wild-type mice ( Figure 4A ), the hepatic Epo mRNA level being so low that it could not be measured in some vehicle-treated animals in these and other experiments reported in this study. FG-4497 administration stabilized Hif-1α and Hif-2α in both tissues, the extent of stabilization of both Hif-αs in the kidney, but not in the liver, being stronger in the P4h-tm -/-than in the wild-type mice ( Figure 4A ). The FG-4497-induced increase in the mean Epo mRNA level in the kidney of the P4h-tm -/-mice was about 2-fold relative to the wild type at 3 weeks and 4-fold at 5
weeks, whereas there was no significant difference between these mice in the liver ( Figure 4A ).
As reported previously, 22 a slight degree of Hif-1α stabilization was seen in the kidney of the whereas no significant difference in the Epo mRNA level was seen between these genotypes in the kidney ( Figure 4C ). Figure 5A ). Administration of FG-4497 increased these values significantly in both genotypes, no difference being seen between the treated P4h-tm -/-and wild-type mice at 3 or 5 weeks, although the reticulocyte counts at 3 weeks were significantly higher in the former than in the latter ( Figure 5A ). Similarly, no difference in hemoglobin and hematocrit values was seen between the vehicle-treated Hif-p4h-2 gt/gt and wild-type ( Figure 5B ) or Hif-p4h-3 -/-and wild-type mice ( Figure 5C ). Administration of FG-4497 increased these values in the Hif-p4h-2 gt/gt mice significantly more than in the wild-type mice already at 3 weeks ( Figure 5B ), whereas in the Hifp4h-3 -/-mice a statistically significant increase relative to the wild type was seen only in the hematocrit value at 5 weeks (P = .05) ( Figure 5C ). The reticulocyte counts were significantly higher in the FG-4497-treated Hif-p4h-3 -/-mice than in the wild-type mice at 4 weeks but not at 3 or 5 weeks ( Figure 5C ).
Effect of FG-4497 on hepatic Hepcidin mRNA concentration
Recent studies have indicated that Hif-2α downregulates Hepcidin expression through an Epomediated increase in erythropoiesis. 8 associated with a markedly decreased serum Epo concentration. 19 The reasons for these decreases are unknown but it has been speculated that an increased number of erythroid progenitors and early erythrocytes may have reduced free Epo protein molecules through increased receptor binding. 19 It has also been reported that several patients with increased hemoglobin values due to heterozygous HIF-P4H-2 mutations have their serum EPO concentrations within the normal range, and in some cases even close to or at the lower limit of normal.
36-38
For 21 Nothing has so far been known about the roles of P4H-TM in the regulation of the response to hypoxia in general or in the regulation of EPO production and erythropoiesis in particular in any mammalian species, although expression levels of several HIF target genes, including epo, have been found to be increased in p4h-tm-deficient zebrafish embryos without any signs of polycythemia. Recent studies have indicated that stabilization of Hif-α is not directly involved in the hypoxic downregulation of hepcidin expression, the effect being mediated by increased Epo expression and a bone-derived systemic signal caused by the increased erythropoiesis. 8, 10 Our data indicating that the Hepcidin mRNA level was decreased in the liver of the FG-4497-treated P4h-tm -/-mice to less 1 4 than half of that in the treated wild type supports our suggestion that erythropoiesis was further increased in the FG-4497-treated P4h-tm -/-mice even though this increase was not large enough to lead to a further increase in the already highly elevated hemoglobin and hematocrit values. showed any change in erythropoiesis, the double mutant mice had significantly increased hemoglobin and hematocrit values.
Another 2-oxoglutarate analogue, FG-2216, which, like FG-4497, inhibits all three HIF-P4Hs, increased EPO production in anephric patients with end stage renal disease as strongly as in healthy subjects, suggesting that it caused effective EPO production in the liver. 41 As the present and previous [18] [19] [20] [21] data indicate that HIF-P4H-2 and P4H-TM are involved in the regulation of EPO production in the kidney but not in the liver, it is evident that a compound inhibiting several HIFP4Hs could be desirable for the treatment of patients with advanced kidney disease. Based on the present data, a compound inhibiting P4H-TM together with some of the HIF-P4H isoenzymes may produce a stronger erythropoietic response and a larger decrease in the hepcidin level than that obtained with a HIF-P4H antagonist lacking P4H-TM inhibition. .056, at 4 weeks P < .02 and at 5 weeks P < .001, hematocrit at 3 weeks P < .005 and at 4 and 5 weeks P < .001; comparison of FG-4497-treated gene-modified mice with vehicle-treated genemodified mice: in A hemoglobin and hematocrit at 3 weeks P < .02, at 5 weeks P < .001, in B hemoglobin and hematocrit P < .001, in C hemoglobin and hematocrit at 3 weeks P < .005 and at 4 and 5 weeks P < .001. Similar comparisons of reticulocyte values are as follows. Comparison of FG-4497-treated wild-type mice with vehicle-treated wild-type mice: in A at 3 weeks P < .005, in C at 3 weeks P < .05 and at 4 weeks P < .001; comparison of FG-4497-treated gene-modified mice with vehicle-treated gene-modified mice in A at 3 weeks P < .002, in C at 3 weeks P < .05 and at 4 weeks For personal use only. on June 9, 2017. by guest www.bloodjournal.org From
